HIV Protease Inhibitors Possessing a Novel, High-Affinity, and Achiral P1'/P2' Ligand with a Unique Pattern of in Vitro Resistance. Importance of a Conformationally-Restricted Template in the Design of Enzyme Inhibitors
J. V. N. Vara Prasad(Pfizer (United States)), John M. Domagala(Pfizer (United States)), Eric L. Reyner, Peter J. Tummino(Intarcia Therapeutics (United States)), Robert Guttendorf, Barbra H. Stewart, John R. Rubin(Pfizer (United States)), Donna Ferguson(Pfizer (United States)), Elizabeth A. Lunney(Pfizer (United States))
Cited by 30
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550